Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Zynex, Inc. (ZYXI)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
12.07-0.30 (-2.43%)
At close: 4:00PM EDT
12.07 0.00 (0.00%)
After hours: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close12.37
Open12.45
Bid11.90 x 800
Ask12.13 x 900
Day's Range12.05 - 12.46
52 Week Range10.66 - 22.89
Volume128,016
Avg. Volume287,526
Market Cap420.6M
Beta (5Y Monthly)0.82
PE Ratio (TTM)79.93
EPS (TTM)0.15
Earnings DateOct 25, 2021 - Oct 29, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateDec 31, 2018
1y Target Est23.40
  • PR Newswire

    Zynex Schedules 2021 Third Quarter Earnings Call

    Zynex, Inc. (Nasdaq: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, announced today that it will host the Company's 2021 third quarter earnings investor webcast on Tuesday, November 2, 2021 at 2:15 p.m. Mountain Time (4:15 p.m. Eastern Time.)

  • Zacks

    Wall Street Analysts Believe Zynex Inc. (ZYXI) Could Rally 87%: Here's is How to Trade

    The mean of analysts' price targets for Zynex Inc. (ZYXI) points to an 86.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

  • PR Newswire

    Zynex Announces 70% Order Growth and Increases Q3 2021 Adjusted EBITDA Estimate

    Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in manufacturing and selling non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced orders and an increased Adjusted EBITDA estimate for Q3 2021.

Advertisement
Advertisement